Table 3.

Bivariate multinomial logistic regressions of tablet naltrexone adoption

Variable	Sustainer vs. nonadopter b (SE) and RRR [95% CI]	Discontinuer vs. nonadopter b (SE) and RRR [95% CI]	Later adopter vs. nonadopter b (SE) and RRR [95% CI]
For profit	−0.140(0.381)	−0.511 (0.479)	−0.784 (0.443)
	0.869 [0.412, 1.832]	0.600[0.235,1.534]	0.457 [0.192, 1.089]
Hospital	0.823 (0.367)*	0.686 (0.428)	0.398 (0.370)
	2.277[1.110,4.672]	1.985[0.858,4.591]	1.489(0.720,3.077)
Size	0.482 (0.156)**	0.153 (0.178)	0.481 (0.160)**
	1.619 [1.193, 2.196]	1.165 [0.821, 1.652]	1.618[1.182,2.216]
Accredited	1.432 (0.481)**	0.892 (0.503)	1.164 (0.459)**
	4.188 [1.631, 10.753]	2.441[0.911,6.538]	3.202 [1.301, 7.876]
% Revenues from	0.023 (0.007)**	0.015 (0.007)*	0.007 (0.007)
private insurance	1.024 [1.009, 1.040]	1.020 [1.005, 1.034]	1.011 [0.998, 1.024]
% Referrals from the	−0.053 (0.015)**	−0.033 (0.012)**	−0.032 (0.010)**
criminal justice system	0.948 [0.921, 0.976]	0.969 [0.950, 0.989]	0.967 [0.945, 0.990]
12-Step attendance	0.149(0.398)	1.003(0.577)	−0.202 (0.392)
required	1.161[0.533,2.5311]	2.727 [0.880, 8.455]	0.817 [0.379, 1.761]
No. of medical staff	0.047 (0.014)**	0.017 (0.020)	0.050 (0.014)**
	1.048 [1.019, 1.078]	1.017 [0.978, 1.057]	1.052 [1.022, 1.082]
Use SSRIs	2.148 (0.457)**	2.037 (0.531)**	1.242 (0.390)**
	8.571 [3.501, 20.987]	7.667 [2.710, 21.691]	3.462 [1.612,7.433]
Participated in research	0.243 (0.369)	0.246 (0.430)	0.734 (0.374)*
	1.275[0.619,2.628]	1.275[0.619,2.628]	2.084[1.002,4.337]

Notes: Bold indicates statistical significance. RRR = relative risk ratio; 95% CI = 95% confidence interval; SSRI = selective serotonin reuptake inhibitor.

^*p < .05;

^**p < .01.